Background: Performance on episodic, semantic, and working memory tests is impaired in
Alzheimer's disease (AD)-type dementia, but it is unclear which type of memory test is most …

Background: Data on the association of memory performance with cerebrospinal fluid (CSF)
biomarkers of Alzheimer's disease (AD) are inconsistent. The Consortium to Establish a …

The objective was to study the association between cerebrospinal fluid (CSF) levels of
amyloid-β (Aβ) 1-42, t-tau, and p-tau and cognitive performance along the Alzheimer's …

Decreased delayed recall, decreased amyloid-β peptides (Aβ 1–42), and increased tau
protein concentration in cerebrospinal fluid (CSF) are generally regarded to be valid …

Numerous studies have shown that Alzheimer's Disease (AD) pathology begins before the
onset of clinical symptoms. Because therapies are likely to be more effective if they are …

Objective To study risk factors for decreasing aβ1–42 concentrations in cerebrospinal fluid
(CSF) in cognitively unimpaired individuals with initially normal amyloid and tau markers …

Cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau have been studied as markers of
Alzheimer's disease (AD). Combined Aβ 42 and t-tau distinguishes AD from healthy controls …

Standard markers in cerebrospinal fluid (CSF), as soluble amyloid beta 1–42 (Aβ1–42) and
total tau protein (t-tau), may contribute to dementia subtypes diagnostic accuracy. Yet, their …

Given the need for tools for early and accurate diagnosis, prediction of disease progression,
and monitoring efficacy of therapeutic agents for AD, the study of cerebrospinal fluid (CSF) …

The pathophysiological processes underlying Alzheimer's disease (AD) are hypothesized to
begin years to decades before clinical symptom onset, while individuals are still cognitively …